Antiplatelet Therapy After Placement of a Drug-Eluting Stent: A Review of Efficacy and Safety Studies

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2265-2281

  Mohammad, Rima A ^a   Goldberg, Tamara ^b,c   Dorsch, Michael P ^d,e   Cheng, Judy W M ^f,g  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c KINGS COUNTY HOSPITAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^f MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiplatelet; Aspirin; Cilostazol; Clopidogrel; Drug eluting stent; Prasugrel; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; PRASUGREL; RAPAMYCIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; COHORT ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW;

ASPIRIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79951821259     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.003     Document Type: Review

References (49)

1. Grüntzig A.R., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61-68.
2. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994, 331:489-495. Benestent Study Group.
3. Fattori R., Piva T. Drug-eluting stents in vascular intervention. Lancet 2003, 361:247-249.
4. Bennett M.R., O'Sullivan M. Mechanisms of angioplasty and stent restenosis: Implications for design of rational therapy. Pharmacol Ther 2001, 91:149-166.
5. Williams D.O., Holubkov R., Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute Registries. Circulation 2000, 102:2945-2951.
6. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term clinical outcome. Circulation 1999, 100:1872-1878.
7. Virmani R., Kolodgie F.D., Farb A., Lafont A. Drug eluting stents: Are human and animal studies comparable?. Heart 2003, 89:133-138.
8. Bennett M.R. In-stent stenosis: Pathology and implications for the development of drug eluting stents. Heart 2003, 89:218-224.
9. Schömig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084-1089.
10. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998, 339:1665-1671. Stent Anticoagulation Restenosis Study Investigators.
11. Baim D.S., Carrozza J.P. Stent thrombosis. Closing in on the best preventive treatment. Circulation 1997, 95:1098-1100.
12. Waksman R., Ajani A.E., White R.L., et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001, 103:2332-2335.
13. Serruys P.W., Emanuelsson H., van der Giessen W., et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996, 93:412-422.
14. Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995, 91:1676-1688.
15. Jeremias A., Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008, 148:234-238.
16. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019. SCAAR Study Group.
17. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007, 356:989-997.
18. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
19. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008.
20. Thrombosis associated with coronary drug-eluting stents Accessed September 9, 2009. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=61.
21. Cutlip D. Impact of stent thrombosis on outcomes of death and MI after drug-eluting stenting. Importance of standard definitions and analytical methods Accessed February 23, 2008. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph1_03_Cutlip.pdf.
22. Kandzari D.E., Leon M.B. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006, 19:405-413.
23. Fiorentino R.P. Stent thrombosis: The implications of broader DES use Accessed February 23, 2008. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph1_18_Fiorention-FDA.pdf.
24. Uchida T., Farb A., Holton A., Duggirala H. FDA summary FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents, Accessed February 23, 2008. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph1_17_FDA%20Summary.pdf.
25. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005, 45:2088-2092.
26. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
27. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113.
28. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113:e166-e286. American College of Cardiology/American Heart Associaiton Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).
29. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007, 115:813-818. American Heart Association, American College of CardiologyAmerican College of Cardiology, Society for Cardiovascular Angiography and InterventionsSociety for Cardiovascular Angiography and Interventions, American College of SurgeonsAmerican College of Surgeons, American Dental AssociationAmerican Dental Association, American College of PhysiciansAmerican College of Physicians.
30. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006, 48:2584-2591. BASKET-LATE Investigators.
31. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007, 116:745-754.
32. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007, 297:159-168.
33. Kimura T., Morimoto T., Nakagawa Y., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009, 119;:987-995. j-Cypher Registry Investigators.
34. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005, 111:2099-2106.
35. Lee S.W., Park S.W., Kim Y.H., et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long Trial). Am J Cardiol 2007, 100:1103-1108. DECLARE-Long Study Investigators.
36. Lee S.W., Park S.W., Kim Y.H., et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008, 51:1181-1187.
37. Chen K.Y., Rha S.W., Li Y.J., et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009, 119:3207-3214. Korea Acute Myocardial Infarction Registry Investigators.
38. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015. TRITON-TIMI 38 Investigators.
39. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised, controlled trial. Lancet 2009, 373:723-731. TRITON-TIMI 38 Investigators.
40. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323. SIRIUS Investigators.
41. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
42. Artang R., Dieter R.S. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 2007, 99:1039-1043.
43. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002, 288:2411-2420. CREDO Investigators (Clopidogrel for the Reduction of Events During Observation), [published correction appears in JAMA. 2003;289:987].
44. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102:624-629. CLASSICS Investigators.
45. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY Study. JAMA 2005, 294:1224-1232. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators.
46. Latib A., Morici N., Cosgrave J., et al. Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. Am J Cardiol 2008, 102:1477-1481.
47. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987, 76:142-154.
48. Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241. [published corrections appear in J Am Coll Cardiol. 2010;55:612 and J Am Coll Cardiol. 2009;54:2464].
49. Guidance for industry. Coronary drug-eluting stents-nonclinical and clinical studies US Food and Drug Administration, Accessed December 3, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM228704.pdf.